Levosalbutamol

Generic Name: Levosalbutamol

Brand Names: Xopenex

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₁NO_₃

CAS Number: 34391-04-3

Unique Ingredient Identifier: EDN2NBH5SS

Background: Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Salbutamol has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).

Indication: Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.

Associated Conditions: Bronchospasm

Associated Therapies: -

Clinical Trials

Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.

Phase 4

Conditions: Hyperkalemia

Interventions: Drug: Levalbuterol
Drug: Albuterol

First Posted Date: 2021-12-30

Last Posted Date: 2021-12-30

Lead Sponsor: University of Aleppo

Target Recruit Count: 30

Registration Number: NCT05173584

Locations: 🇸🇾
Aleppo University Hospital, Aleppo, Aleppo Provice, Syrian Arab Republic

Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults

Not Applicable

Completed

Conditions: Oxygen Consumption

Interventions: Drug: Albuterol
Drug: Levalbuterol

First Posted Date: 2016-06-16

Last Posted Date: 2020-10-28

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 24

Registration Number: NCT02802111

Aerosolized Beta-Agonist Isomers in Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: levalbuterol
Other: levalbuterol MDI
Device: aerochamber max
Drug: saline
Device: breath actuated nebulizer
Drug: ipratroprium

First Posted Date: 2014-06-23

Last Posted Date: 2014-08-13

Lead Sponsor: Duke University

Target Recruit Count: 10

Registration Number: NCT02170532

COPD Assessment and Management Bundle Versus Usual Care

Not Applicable

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Device: Spirometry test
Drug: Levalbuterol

First Posted Date: 2013-04-16

Last Posted Date: 2019-12-24

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 56

Registration Number: NCT01833026

Locations: 🇺🇸
University of Illinois, Chicago, Illinois, United States

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo (for Dupilumab)
Drug: Dupilumab
Drug: Fluticasone/Salmeterol combination therapy
Drug: Fluticasone monotherapy
Drug: Albuterol
Drug: Levalbuterol

First Posted Date: 2011-03-11

Last Posted Date: 2017-06-08

Lead Sponsor: Sanofi

Target Recruit Count: 104

Registration Number: NCT01312961

Locations: 🇺🇸
Investigational Site Number 840003, Minneapolis, Minnesota, United States
🇺🇸
Investigational Site Number 840006, Saint Louis, Missouri, United States
🇺🇸
Investigational Site Number 840047, Anaheim, California, United States

and more 47 locations

Effect of Nebulized Bronchodilators on Heart Rate

Phase 4

Completed

Conditions: Sepsis
COPD
Shock

Interventions: Drug: Levalbuterol
Drug: Albuterol

First Posted Date: 2010-06-28

Last Posted Date: 2015-10-23

Lead Sponsor: Fahim Khorfan, MD

Target Recruit Count: 89

Registration Number: NCT01151579

Locations: 🇺🇸
Genesys Regional Medical Center, Grand Blanc, Michigan, United States

Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: placebo
Drug: racemic salbutamol
Drug: levosalbutamol

First Posted Date: 2009-01-28

Last Posted Date: 2019-04-12

Lead Sponsor: University of Dundee

Target Recruit Count: 30

Registration Number: NCT00831376

Locations: 🇬🇧
Asthma and Allergy Research Group, Dundee, Angus, United Kingdom

Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol

Phase 4

Withdrawn

Conditions: Asthma

Interventions: Drug: racemic salbutamol
Drug: placebo
Drug: levosalbutamol

First Posted Date: 2009-01-28

Last Posted Date: 2012-06-12

Lead Sponsor: University of Dundee

Registration Number: NCT00830882

Locations: 🇬🇧
Asthma and Allergy Research Group, Dundee, Angus, United Kingdom

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

Phase 4

Terminated

Conditions: Acute Asthma

Interventions: Drug: arformoterol (RR formoterol)
Drug: levalbuterol
Drug: placebo

First Posted Date: 2009-01-09

Last Posted Date: 2023-05-24

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 2

Registration Number: NCT00819637

Locations: 🇺🇸
Henry Ford Hospital Emergency Department, Detroit, Michigan, United States

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Levalbuterol
Drug: Placebo
Drug: Levalbuterol UDV TID

First Posted Date: 2008-12-17

Last Posted Date: 2014-07-28

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 197

Registration Number: NCT00809757

Locations: 🇺🇸
Dayton Clinical Research, Dayton, Ohio, United States
🇺🇸
ADAC Research, PA, Greenville, South Carolina, United States
🇺🇸
Sneeze, Wheeze & Itch Associates LLC, Normal, Illinois, United States

and more 43 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy